跳到正文
原文
Endpoints News 生物医药· Lei Lei Wu·· 2026-10-14AI 评分47

Vir Biotech与Gilead达成实体瘤T细胞接合器合作,获6500万美元首付款

Vir makes solid tumor T cell engager deal with Gilead

AI 导读

Vir Biotechnology与Gilead达成一项针对实体瘤T细胞接合器的合作,Gilead将向Vir支付6500万美元首付款,文中提及Vir CEO Marianne De Backer近期已多次达成交易。

正文

Vir Biotech­nol­o­gy and its CEO Mar­i­anne De Backer have notched yet an­oth­er deal, this time with Gilead.

Gilead will pay Vir $65 mil­lion up­front, with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news